Journal of Antimicrobial Chemotherapy最新文献

筛选
英文 中文
Understanding integrase inhibitor resistance in Angola: a comparative analysis of INSTI-naive and INSTI-experienced individuals. 了解整合酶抑制剂在安哥拉的耐药性:对未感染和有感染经验的个体的比较分析。
IF 4.1 2区 医学
Journal of Antimicrobial Chemotherapy Pub Date : 2026-11-03 DOI: 10.1093/jac/dkag355
Bárbara Pocongo, Maria Furtado, Cláudia Bernardi, Lucrécia Jacinto, Aulória José, Jaime Urica, Rosa Torres, Francisco Vunge, Beatriz Almeida, Michael R Jordan, Carlos Jesus, Monick Lindenmeyer Guimarães, Cíntia Mayumi Ahagon, Giselle Lopes, Luís Brígido, Seth Inzaule, Ana B Abecasis, Ricardo Parreira, João Piedade, Victor Pimentel
{"title":"Understanding integrase inhibitor resistance in Angola: a comparative analysis of INSTI-naive and INSTI-experienced individuals.","authors":"Bárbara Pocongo, Maria Furtado, Cláudia Bernardi, Lucrécia Jacinto, Aulória José, Jaime Urica, Rosa Torres, Francisco Vunge, Beatriz Almeida, Michael R Jordan, Carlos Jesus, Monick Lindenmeyer Guimarães, Cíntia Mayumi Ahagon, Giselle Lopes, Luís Brígido, Seth Inzaule, Ana B Abecasis, Ricardo Parreira, João Piedade, Victor Pimentel","doi":"10.1093/jac/dkag355","DOIUrl":"10.1093/jac/dkag355","url":null,"abstract":"<p><strong>Background: </strong>Africa remains a major epicentre of the global HIV epidemic, with Central Africa exhibiting extensive HIV-1 genetic diversity that may influence the emergence and transmission of drug resistance mutations. Following World Health Organization recommendations, Angola initiated the national transition to dolutegravir (DTG)-based antiretroviral therapy (ART) in 2021. This study evaluated the frequency, patterns and temporal trends of HIV-1 drug resistance mutations before and after DTG implementation (2019-23), while also characterizing HIV-1 genetic diversity across Angolan provinces outside Luanda.</p><p><strong>Methods: </strong>A retrospective observational analytical study comparing pre- and post-Integrase strand transfer inhibitor (INSTI) introduction periods was conducted using plasma samples and dried blood spot cards from 17 provinces of Angola.</p><p><strong>Results: </strong>Of the 201 samples analysed, 102 were successfully sequenced for at least one coding region [protease (n = 65); reverse transcriptase (n = 66); integrase (IN) (n = 86)], comprising 48 INSTI-naive people living with HIV and 54 INSTI-experienced people living with HIV samples. Subtype C was the most prevalent (21.6%), followed by unique recombinant forms (20.6%), A1 (15.7%), F1 (13.7%), CRF02_AG (10.8%), G (8.8%) and other subtypes or recombinants (8.8%). Resistance to non-nucleoside reverse transcriptase inhibitors was the most common (68.2%; 95% CI 56.2-78.2), followed by nucleoside reverse transcriptase inhibitors (48.5%; 95% CI 36.8-60.3). Resistance to protease inhibitors (PIs) and INSTIs was lower, observed in 1.5% (95% CI 0.3-8.2) and 3.5% (95% CI 1.2-9.8), respectively.</p><p><strong>Conclusions: </strong>In this analysis, substantial HIV-1 genetic and epidemiological complexity was observed. In the context of the rapid scale-up of DTG-based ART, continued surveillance of INSTI resistance mutations has become increasingly important to inform evidence-based public health strategies aimed at preventing the transmission of drug-resistant HIV strains and optimizing ART regimens at the population level.</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":"81 12","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13729367/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149321465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antimicrobial resistance of Shigella spp. in South Australia and its detection using WGS. 南澳大利亚地区志贺氏菌的耐药性及其WGS检测。
IF 4.1 2区 医学
Journal of Antimicrobial Chemotherapy Pub Date : 2026-11-03 DOI: 10.1093/jac/dkag343
Helena Torpy, Arshdeep Kaur Mudhar, Lex E X Leong, Casey Moore, Helen Hocking, Emily Rowe, Lito E Papanicolas
{"title":"Antimicrobial resistance of Shigella spp. in South Australia and its detection using WGS.","authors":"Helena Torpy, Arshdeep Kaur Mudhar, Lex E X Leong, Casey Moore, Helen Hocking, Emily Rowe, Lito E Papanicolas","doi":"10.1093/jac/dkag343","DOIUrl":"https://doi.org/10.1093/jac/dkag343","url":null,"abstract":"<p><strong>Background: </strong>The use of WGS for antimicrobial susceptibility testing (AST) is limited by incomplete understanding of the correlation of genetic variants with phenotypic antimicrobial resistance (AMR).</p><p><strong>Objectives: </strong>A 5 year retrospective review of Shigella isolates in South Australia was undertaken to compare the results of phenotypic AST with WGS-derived AMR to determine the ability of WGS to infer phenotypic resistance.</p><p><strong>Methods: </strong>Pure colonies from confirmed Shigella isolates were selected and DNA extracted using the automated QIASymphony platform. Isolates were sequenced using an Illumina NextSeq platform. The Comprehensive Antibiotic Resistance Database (CARD) was used with the AMR screening tool 'ABRicate' to screen assemblies for the presence of intrinsic AMR genes. In addition, the AMRFinderPlus tool with NCBI's compiled database National Database of Antibiotic-Resistant Organisms (NDARO) was used to detect resistance-conferring point mutations, and to verify intrinsic AMR gene screening. The WGS and phenotypic AST results were compared.</p><p><strong>Results: </strong>There was 96% correlation between phenotypic and WGS-AST. The sensitivity of WGS-AST for prediction of AMR varied according to the antimicrobial: ceftriaxone (100%), azithromycin (100%), ciprofloxacin (100%), ampicillin (88.7%) and trimethoprim/sulfamethoxazole (93.5%). WGS failed to detect resistance in 17 ampicillin-resistant isolates, constituting very major errors. False-positive results included the detection of AmpC blaCMY59 in four ceftriaxone-susceptible Shigella flexneri isolates and genotypic ciprofloxacin resistance in two phenotypically susceptible isolates: one carrying qnrS1 and one carrying four quinolone resistance-determining region point mutations.</p><p><strong>Conclusions: </strong>The unexpectedly high rate of false-negative WGS-AST results for detection of ampicillin and trimethoprim/sulfamethoxazole resistance highlights the importance of local validation studies of WGS-AST for specific organism-antimicrobial combinations prior to its use in AMR surveillance.</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":"81 12","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149406351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Changes in sales of medically important antimicrobials for use in livestock animals in Canada following the 2018 federal policy mandating veterinarian prescription. 2018年联邦政策强制兽医处方后,加拿大用于牲畜的重要医用抗菌素销售的变化。
IF 4.1 2区 医学
Journal of Antimicrobial Chemotherapy Pub Date : 2026-11-03 DOI: 10.1093/jac/dkag385
Fiona Emdin, E Jane Parmley, Kevin A Brown, Angelina L Bosman, Carolee A Carson, Valerie Leung, Bradley J Langford, Kevin L Schwartz, Nick Daneman
{"title":"Changes in sales of medically important antimicrobials for use in livestock animals in Canada following the 2018 federal policy mandating veterinarian prescription.","authors":"Fiona Emdin, E Jane Parmley, Kevin A Brown, Angelina L Bosman, Carolee A Carson, Valerie Leung, Bradley J Langford, Kevin L Schwartz, Nick Daneman","doi":"10.1093/jac/dkag385","DOIUrl":"https://doi.org/10.1093/jac/dkag385","url":null,"abstract":"<p><strong>Background: </strong>Antimicrobial resistance (AMR) threatens human and animal health globally, and antimicrobial use in food-animal production is increasing. On 1 December 2018, Canada implemented federal policies requiring medically important antimicrobials (MIAs) for veterinary use to be sold by prescription only and removed growth-promotion claims from labels. We evaluated whether these policy changes were associated with changes in livestock antimicrobial sales.</p><p><strong>Methods: </strong>We conducted a cross-sectional study evaluating annual Canadian livestock antimicrobial sales before (2018) and after (2019-2023) policy implementation. The primary outcome was annual sales of MIAs standardized as mg/kg biomass. Negative binomial regression models estimated associations between the policy and antimicrobial sales. A secondary difference-in-differences model assessed route-specific effects using injectable products as a control group because these products were already prescription-only and not labelled for growth promotion. Secondary regression models evaluated antimicrobial class, province, species, and Health Canada importance in the human medicine category.</p><p><strong>Results: </strong>Mean national MIA sales decreased by 11% between 2018 and 2019-2023. However, federal policy changes were not associated with a significant reduction in overall antimicrobial sales [incidence rate ratio (IRR) 0.89, 95% CI 0.29-2.68; P = 0.83]. No significant effects were identified in route-specific, antimicrobial class, province-level, or species-level analyses. The difference-in-differences analysis also showed no significant policy effect (IRR 0.89, 95% CI 0.06-12.9; P = 0.93).</p><p><strong>Conclusions: </strong>Although antimicrobial sales declined overall, we found no detectable association between Canada's 2018 veterinary policy changes and livestock antimicrobial sales. However, the analysis had limited statistical power, meaning that smaller but potentially meaningful changes in antimicrobial sales may have gone undetected. Continued evaluation of interventions is needed to identify strategies to reduce antimicrobial use and mitigate AMR in agriculture.</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":"81 12","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13759975/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149406352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world experience with cefepime/zidebactam under compassionate use. 头孢吡肟/齐地巴坦在体恤使用下的真实体验。
IF 4.1 2区 医学
Journal of Antimicrobial Chemotherapy Pub Date : 2026-11-03 DOI: 10.1093/jac/dkag324
Dilip K Dubey, Subramanian Swaminathan, Praveen K Tirlangi, Vishnu Rao Polati, Rajeev Soman, Rasika Sirsat, Abdul Ghafur, Raman Gaikwad, Vasant Nagvekar, Abi S Manesh, Irfana Mohammed, Harshad S Limaye, Pooja H Shah, Ankit Mittal, Pratik Y Patil, Nitin Gupta, Umang Agrawal, Manish Soneja, Sowmya Sridharan, Surabhi Madan, Sandeep K Mitra, Monalisa Sahu, Ayesha J Sunavala, Kedar K Toraskar, Tanu Singhal, Ashwini R Tayade, Neha Gupta, Anjely P Sebastian, Vijil Rahulan, Suneetha Narreddy, Erlinda R Ulloa, William R Miller, Vidya Krishna, Honey S Savla, Radhika N Sarda, Nitin Bansal, Shalmali B Inamdar, Harshith B Kadnur, Siddhant Shetty, Vikas Deswal, Elisabeth E Adderson, Samuel L Aitken, David van Duin, Timothy William, Andrew Shorr, Balaji Veeraraghavan, Thomas P Lodise
{"title":"Real-world experience with cefepime/zidebactam under compassionate use.","authors":"Dilip K Dubey, Subramanian Swaminathan, Praveen K Tirlangi, Vishnu Rao Polati, Rajeev Soman, Rasika Sirsat, Abdul Ghafur, Raman Gaikwad, Vasant Nagvekar, Abi S Manesh, Irfana Mohammed, Harshad S Limaye, Pooja H Shah, Ankit Mittal, Pratik Y Patil, Nitin Gupta, Umang Agrawal, Manish Soneja, Sowmya Sridharan, Surabhi Madan, Sandeep K Mitra, Monalisa Sahu, Ayesha J Sunavala, Kedar K Toraskar, Tanu Singhal, Ashwini R Tayade, Neha Gupta, Anjely P Sebastian, Vijil Rahulan, Suneetha Narreddy, Erlinda R Ulloa, William R Miller, Vidya Krishna, Honey S Savla, Radhika N Sarda, Nitin Bansal, Shalmali B Inamdar, Harshith B Kadnur, Siddhant Shetty, Vikas Deswal, Elisabeth E Adderson, Samuel L Aitken, David van Duin, Timothy William, Andrew Shorr, Balaji Veeraraghavan, Thomas P Lodise","doi":"10.1093/jac/dkag324","DOIUrl":"10.1093/jac/dkag324","url":null,"abstract":"<p><strong>Introduction: </strong>Cefepime/zidebactam is a β-lactam/β-lactam enhancer combination with activity against carbapenem-resistant (CR) Gram-negative pathogens, including metallo-β-lactamase (MBL)-producing organisms. Before regulatory approval, cefepime/zidebactam was available through a compassionate-use programme for patients with CR Gram-negative infections who had limited available treatment options.</p><p><strong>Methods: </strong>We conducted a retrospective, multi-country analysis of patients who received cefepime/zidebactam through compassionate use between 2022 and 2025. Data included demographics, comorbidities, acute complications, prior antibiotic exposure, infection characteristics, microbiology, treatment details, and investigator-assessed outcomes.</p><p><strong>Results: </strong>Eighty-five patients were included (median age 48 years; 57.6% in an intensive care unit at initiation). Primary infections included pneumonia/respiratory infection (30.6%), bone and joint infection (24.7%), and complicated urinary tract infection/pyelonephritis (14.1%). Pseudomonas aeruginosa was the predominant pathogen (77.6%), followed by Klebsiella pneumoniae (14.1%) and Acinetobacter baumannii (11.8%); infections involving at least two Gram-negative pathogens occurred in 10.6%. Among isolates with available genotypic data, MBLs were common and predominantly NDM. The cefepime/zidebactam minimum inhibitory concentration (MIC)50 and MIC90 were 8 and 32 mg/L, respectively. Investigator-assessed clinical success at the end of therapy was achieved in 88.2% of patients (95% CI, 79.7-93.5), and microbiological eradication in 89.4% (95% CI, 81.1-94.3); on-therapy mortality was 10.6% (95% CI, 5.7-18.9). Treatment-emergent adverse events occurred in five patients (5.9%, 95% CI, 2.5-13.0), with one discontinuation.</p><p><strong>Conclusions: </strong>In this uncontrolled compassionate-use case series, cefepime/zidebactam treatment was accompanied by high investigator-assessed clinical success and microbiological eradication in patients with severe infections caused by CR Gram-negative pathogens. These observations require confirmation in prospective controlled studies.</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":"81 12","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13748750/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149378969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comment on: Artificial intelligence for improving decision-making in bacterial infection management: a narrative review. 点评:人工智能在改善细菌感染管理决策中的应用:叙述性综述。
IF 4.1 2区 医学
Journal of Antimicrobial Chemotherapy Pub Date : 2026-11-03 DOI: 10.1093/jac/dkag298
R Subha, V T Kruthika
{"title":"Comment on: Artificial intelligence for improving decision-making in bacterial infection management: a narrative review.","authors":"R Subha, V T Kruthika","doi":"10.1093/jac/dkag298","DOIUrl":"https://doi.org/10.1093/jac/dkag298","url":null,"abstract":"","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":"81 12","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149406353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rethinking amoxicillin dosing in the ICU: the predominant role of renal function in drug exposure. 重新思考阿莫西林在ICU的剂量:肾功能在药物暴露中的主要作用。
IF 4.1 2区 医学
Journal of Antimicrobial Chemotherapy Pub Date : 2026-11-03 DOI: 10.1093/jac/dkag362
Margot Reber, Sophie Perinel Ragey, Nicolas Maillard, Pascal Beuret, Vincent Gauthier, Jérôme Morel, Guillaume Thiery, Manon Launay
{"title":"Rethinking amoxicillin dosing in the ICU: the predominant role of renal function in drug exposure.","authors":"Margot Reber, Sophie Perinel Ragey, Nicolas Maillard, Pascal Beuret, Vincent Gauthier, Jérôme Morel, Guillaume Thiery, Manon Launay","doi":"10.1093/jac/dkag362","DOIUrl":"10.1093/jac/dkag362","url":null,"abstract":"<p><strong>Background: </strong>Amoxicillin is commonly used in ICU and dosing is typically prescribed either as total daily amounts or based on body weight, with adjustments made when estimated glomerular filtration rate (eGFR) falls below 30 mL/min/1.73 m2. However, ICU patients often exhibit altered pharmacokinetics and renal function, potentially impacting drug exposure.</p><p><strong>Objectives: </strong>The aim of this study is to evaluate the influence of renal function and body weight on amoxicillin exposure.</p><p><strong>Methods: </strong>This multicentre retrospective ICU study assessed amoxicillin exposure using plasma concentrations and concentration-to-dose (C/D) ratios in patients receiving continuous infusion. Renal function was evaluated using indexed and deindexed CKD-EPI equations, analysed as both continuous and categorical variables. Theoretical daily doses required to reach target concentrations were estimated from C/D ratios.</p><p><strong>Results: </strong>Ninety-two patients (including 30 obese, 32%) with a median eGFR of 90 [63-106] mL/min/1.73 m2 were included. Regarding amoxicillin exposure, 45 patients (49%) achieved concentrations within the predefined therapeutic target range of 40-80 mg/L, while 37 patients (40%) had concentrations below 40 mg/L, and 10 patients (11%) exceeded 80 mg/L. Amoxicillin concentrations and C/D ratios increased as renal function declined. Renal function was the primary independent determinant of concentration, while obesity had no significant effect on exposure or absolute daily dose. After deindexing eGFR, differences between obese and non-obese patients disappeared, and the inverse relationship between renal function and C/D ratio remained.</p><p><strong>Conclusions: </strong>Amoxicillin exposure during continuous infusion is mainly driven by renal function rather than body weight. Dose adjustment based on deindexed GFR may be appropriate, with higher doses needed in patients with normal or augmented renal function.</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":"81 12","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149406355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In vitro activity of cefiderocol against Burkholderia cepacia complex and Burkholderia gladioli clinical isolates from cystic fibrosis patients in the United States. 头孢地罗对美国囊性纤维化患者中产洋葱伯克霍尔德菌复合物和剑兰伯克霍尔德菌临床分离株的体外活性研究
IF 4.1 2区 医学
Journal of Antimicrobial Chemotherapy Pub Date : 2026-10-06 DOI: 10.1093/jac/dkag347
Maria F Mojica, Elise T Zeiser, Scott A Becka, Lindsay J Caverly, John J Lipuma, Robert A Bonomo, Krisztina M Papp-Wallace
{"title":"In vitro activity of cefiderocol against Burkholderia cepacia complex and Burkholderia gladioli clinical isolates from cystic fibrosis patients in the United States.","authors":"Maria F Mojica, Elise T Zeiser, Scott A Becka, Lindsay J Caverly, John J Lipuma, Robert A Bonomo, Krisztina M Papp-Wallace","doi":"10.1093/jac/dkag347","DOIUrl":"10.1093/jac/dkag347","url":null,"abstract":"<p><strong>Background: </strong>Burkholderia cepacia complex (Bcc) and Burkholderia gladioli are intrinsically multidrug-resistant pathogens that cause chronic pulmonary infections in individuals with cystic fibrosis (CF) and severe infections in other vulnerable populations. Therapeutic options remain limited as resistance to commonly used agents continues to emerge.</p><p><strong>Objectives: </strong>To evaluate the in vitro activity of cefiderocol against a collection of Bcc and B. gladioli isolates from individuals with CF in the USA and to compare these findings with historical susceptibility data for 16 other antimicrobial agents.</p><p><strong>Methods: </strong>A total of 150 clinical isolates representing multiple Bcc species and B. gladioli were tested. Cefiderocol MICs were determined using iron-depleted broth microdilution (ID-BMD) and iron-depleted agar dilution (ID-AD). Species-specific MIC distributions were assessed, and cefiderocol activity was compared with historical MIC data for 16 other antimicrobial agents previously tested against the same isolate panel. Mechanistic studies evaluated blaPenA expression and hydrolysis of cefiderocol by purified PenA1.</p><p><strong>Results: </strong>Cefiderocol MIC50 and MIC90 values were 0.06 and 8 mg/L, and 0.03 and 8 mg/L, respectively, by both ID-BMD and ID-AD. Low MIC90 values were observed for Burkholderia cenocepacia, B. cepacia, B. gladioli, and most 'other Bcc' species, whereas elevated MIC90 values were detected for Burkholderia multivorans and Burkholderia vietnamiensis. Cefiderocol demonstrated the lowest MIC50 values when compared with historical data for 16 other agents; did not induce blaPen expression; and was not hydrolysed by purified PenA1.</p><p><strong>Conclusions: </strong>Cefiderocol demonstrated broad in vitro activity against Bcc and B. gladioli isolates from individuals with CF and showed stability against key β-lactamase-mediated resistance mechanisms.</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":"81 11","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13712140/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149286991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Determinants of levofloxacin prophylaxis failure in high-risk haematology patients: a prospective study integrating resistant colonization and pharmacokinetic/pharmacodynamic target attainment-authors' response. 高危血液病患者左氧氟沙星预防失败的决定因素:一项整合耐药定植和药代动力学/药效学目标实现的前瞻性研究——作者的反应
IF 4.1 2区 医学
Journal of Antimicrobial Chemotherapy Pub Date : 2026-10-06 DOI: 10.1093/jac/dkag342
Cemre Boşnak, Gökhan Metan, Pınar Zarakolu, Elifcan Aladağ Karakulak, Aslı Pınar, Hakan Göker, Jason A Roberts, Maria Patricia Hernandez-Mitre, Murat Akova
{"title":"Determinants of levofloxacin prophylaxis failure in high-risk haematology patients: a prospective study integrating resistant colonization and pharmacokinetic/pharmacodynamic target attainment-authors' response.","authors":"Cemre Boşnak, Gökhan Metan, Pınar Zarakolu, Elifcan Aladağ Karakulak, Aslı Pınar, Hakan Göker, Jason A Roberts, Maria Patricia Hernandez-Mitre, Murat Akova","doi":"10.1093/jac/dkag342","DOIUrl":"https://doi.org/10.1093/jac/dkag342","url":null,"abstract":"","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":"81 11","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149164816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
No clinically relevant QTc prolongation with ceftibuten or ledaborbactam etzadroxil: concentration-QTc analyses from two phase I studies. 头孢布酮或利来博巴坦依扎罗西没有临床相关的QTc延长:来自两个I期研究的浓度-QTc分析。
IF 4.1 2区 医学
Journal of Antimicrobial Chemotherapy Pub Date : 2026-10-06 DOI: 10.1093/jac/dkag365
Borje Darpo, Hongqi Xue, Kamal A Hamed, Karine Litherland, Marc Engelhardt, Kathryn Lowe, Paul C McGovern
{"title":"No clinically relevant QTc prolongation with ceftibuten or ledaborbactam etzadroxil: concentration-QTc analyses from two phase I studies.","authors":"Borje Darpo, Hongqi Xue, Kamal A Hamed, Karine Litherland, Marc Engelhardt, Kathryn Lowe, Paul C McGovern","doi":"10.1093/jac/dkag365","DOIUrl":"10.1093/jac/dkag365","url":null,"abstract":"<p><strong>Objective: </strong>Ceftibuten and ledaborbactam etzadroxil are being developed as an oral fixed-dose combination for the treatment of complicated urinary tract infections caused by multidrug-resistant Enterobacterales. This study evaluated their effects on cardiac repolarization using concentration-QTc analyses.</p><p><strong>Methods: </strong>ECG and pharmacokinetic data from two randomized, single-centre, double-blind, placebo-controlled, phase I, dose-escalation studies in healthy adults (ClinicalTrials.gov: NCT04314206 and NCT04243863) were analysed using concentration-QTc modelling. Thirty-six participants were randomized to the ceftibuten study (27 active, nine placebo) and 48 to the ledaborbactam etzadroxil study (36 active, 12 placebo). Linear mixed-effects models characterized the relationship between plasma concentrations and placebo-corrected change from baseline in Fridericia-corrected QT interval (ΔΔQTcF). Model-based predictions estimated QTc effects across observed and clinically relevant plasma concentrations.</p><p><strong>Results: </strong>Neither agent produced clinically relevant changes in ECG parameters. Concentration-QTc analyses demonstrated no statistically or clinically meaningful relationship between plasma concentrations and ΔΔQTcF. An effect on ΔΔQTcF exceeding the regulatory threshold of 10 ms could be excluded at plasma concentrations up to 44 µg/mL for cis-ceftibuten (the predominant and more potent isomer), 2.2 µg/mL for trans-ceftibuten, 30.3 µg/mL for ledaborbactam (active drug), and 2.6 µg/mL for ledaborbactam etzadroxil (prodrug). A small, transient, not clinically relevant increase in heart rate was observed with ceftibuten, whereas ledaborbactam etzadroxil had no clinically meaningful effect on heart rate.</p><p><strong>Conclusions: </strong>Ceftibuten and ledaborbactam etzadroxil demonstrated no clinically relevant effects on cardiac repolarization or ECG parameters. Concentration-QTc analyses excluded clinically meaningful QTc effects at and above anticipated therapeutic plasma concentrations, supporting the cardiac safety profile of this oral fixed-dose combination.</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":"81 11","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13691604/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149244855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Updated UK good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT): ensuring quality of care and antimicrobial stewardship in an evolving healthcare landscape. 更新的英国门诊肠外抗菌治疗(OPAT)良好实践建议:在不断发展的医疗保健环境中确保护理质量和抗菌管理。
IF 4.1 2区 医学
Journal of Antimicrobial Chemotherapy Pub Date : 2026-10-06 DOI: 10.1093/jac/dkag327
Ann L Noble, Sanjay Patel, Mark Gilchrist, R Andrew Seaton
{"title":"Updated UK good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT): ensuring quality of care and antimicrobial stewardship in an evolving healthcare landscape.","authors":"Ann L Noble, Sanjay Patel, Mark Gilchrist, R Andrew Seaton","doi":"10.1093/jac/dkag327","DOIUrl":"https://doi.org/10.1093/jac/dkag327","url":null,"abstract":"<p><p>Outpatient parenteral antimicrobial therapy (OPAT) offers safe, effective and patient-centred care for patients with infections requiring IV or complex oral antimicrobial therapy. The UK OPAT Good Practice Recommendations (GPRs) have recently been updated through a systematic literature review, expert consensus and consultation. In this article we outline the key changes in the updated GPRs. There are five new recommendations on (i) self-administration, (ii) OPAT in hard-to-reach groups, (iii) patient education, (iv) developing monitoring protocols for patients on complex oral antimicrobials and on new parenteral administration routes and regimes, and (v) equitable provision of care; and two amended recommendations, on (i) thromboprophylaxis, and (ii) early collaboration with vascular access teams. Overall, the literature demonstrates the increasing confidence of OPAT services in managing complex and comorbid patients, and shows evidence of innovation and collaboration. OPAT has the potential to improve clinical care and antimicrobial stewardship in patients with complex infections in an evolving healthcare landscape.</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":"81 11","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149244815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书